.png)
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery and drug development studies.
Selvita was established in 2007 and currently employs over 900 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. Selvita’s international offices are located in Boston, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.
Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS.
The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.
Furthermore, Selvita provides state-of-the-art analytical services supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and CMC processes by providing contract laboratory services for testing. We have a diverse analytical instrumentation and expertise portfolio, allowing us to meet varied demands, including testing of starting materials, drug substances, intermediates, and final products of small and large molecules. Selvita complies with GMP and GLP requirements to meet the highest industry standards.